20 Mar 2015


This special, one time program enables patients to receive a free Twinject(R) if they currently have an EpiPen(R). Food and Drug Administration (FDA) that contains two doses of epinephrine in a single, compact device.

“Twinject was introduced with the fundamental objective of addressing unmet medical needs for those individuals at risk for anaphylaxis, a life threatening condition,” said Robert W. Keith, President and Chief Operating Officer of Verus Pharmaceuticals. market in over 20 years. Working collaboratively with the medical community and patient advocacy groups, our intent is to provide a continuous stream of innovative products and programs for those at risk for anaphylaxis.”

“It is imperative that all patients at risk for anaphylaxis be fully prepared at all times to address these unpredictable episodes,” said Clifford KOBE 9 W. By visiting the website, patients who currently have an EpiPen can learn how to receive their free Twinject. alone are at risk for anaphylactic episodes, Air Jordan 2011 and underlying incidence rates are expected to continue increasing in future years. Up to eight percent of children have food allergies, with sensitivities to peanuts and tree nuts among children having doubled in the past five Nike LeBron 12 years. The timing, location, pattern (including onset, severity and length) and specific treatment requirements for each future episode cannot be predicted in advance. This is an important feature, as published studies demonstrate that more than one dose of epinephrine may be required for approximately one in three patients to properly address the allergic reaction, with the second dose often needed within 5 10 minutes after the first (references 1,2,3). Furthermore, a recent study demonstrated that only 16% of patients carry two single dose auto injectors at all times (reference 3).

About Verus

Verus Pharmaceuticals is dedicated to improving the lives of children and those who care for them. Verus is building a portfolio of products for the unmet medical needs of children through acquisitions and alliances, with an initial focus on the treatment of asthma, allergies, and related diseases and conditions. Verus is differentiated by its pediatric orientation and its strong financial position and experienced management team, which allows the company to capitalize on an extensive network to build its product portfolio and pursue complementary transactions. The company’s rigorous, disciplined approach to strategic decision Air Jordan 5s making and core competencies in development and commercialization is expected to provide significant value to its partners. The inclusion of forward looking statements should not be regarded as a representation by Verus that any of its plans will be achieved. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in Verus’ business including, without limitation, statements about: its ability to identify appropriate acquisition, licensing, or co development and/or promotion candidates in the future or be able to take advantage of the opportunities it identifies; difficulties or delays in developing, obtaining regulatory approval, manufacturing and commercializing its products; unexpected performance or side effects of its products that could delay or prevent development or commercialization, or that could result in recalls or product liability claims; the scope and validity of patent protection for its products; competition from other pharmaceutical companies; and its ability to obtain additional financing to support its operations. All forward looking statements are qualified in their Air Jordan 10s entirety by this cautionary statement and Verus undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. Verus’ use of this mark in no way implies any affiliation with or sponsorship or endorsement by Dey.

References: 1. Webb L, et al., J Allergy Clin Immunol. 2004;113(suppl 1):S240. Abstract 857 2. Korenblat P, et al., Allergy Asthma Proc. 1999;20:383 386 3.

Leave a Reply

You are visitor no. HTML Hit Counter